Agape ATP Corporation reported QQ3 2025 revenue of $370.6k, up 11.9% year-over-year but down 20.4% sequentially. Gross profit was $239.1k, yielding a gross margin of 64.5%. However, the quarter posted an EBITDA loss of $601.3k and a net loss of $586.8k, driven by a heavy fixed-cost base relative to the small topline. The company’s cost structure—General and Administrative expenses of $751.4k and total operating expenses of $689.8k—drives negative profitability at this scale, signaling the need for material topline growth or cost rationalization to reach break-even. While the product portfolio spans ATP health programs, BEAUNIQUE, and Energetique lines, execution risk remains elevated for a micro-cap entity with an OTC listing and limited operating scale.